This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

MSD Satellite Symposium at BTOG Annual Conference 2021

MSD is proud to be the Diamond sponsor of the British Thoracic Oncology Group (BTOG) in 2021

Prescribing Information

IO treatment in 1L mNSCLC – a focus on PD-L1 <1% patients through case studies

The recording of our Sponsored Satellite Symposium with Dr Riyaz Shah and Dr Stephen V. Liu is now available to watch below.

Prescribing Information

The introduction of immunotherapies, either alone or in combination with chemotherapy, has changed the survival outlook for metastatic non-small-cell lung cancer (NSCLC) patients. Hear first-hand from Dr Stephen V. Liu as he shares his views and experience of prescribing KEYTRUDA® (pembrolizumab) in combination with chemotherapy in PD-L1 non-expressor patients through two patient case studies.


Dr Stephen V. Liu, MD​

Associate Professor at Georgetown University,
Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center

Dr. Liu received his Internal Medicine training at the University of Pennsylvania and completed a fellowship in Hematology and Oncology at the University of Southern California. His current focus is on the development of novel drugs and rational combinations. His research has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology and Cancer Discovery.

Dr Riyaz Shah​ (Chair)

Consultant Medical Oncologist,
Maidstone and Tunbridge Wells NHS Trust,

Dr Riyaz Shah, Consultant Medical Oncologist at Kent Oncology Centre, Maidstone Hospital. Dr Shah qualified from Guy’s and St Thomas Hospitals in 1994. He was an Imperial Cancer Research Fund Clinical Research Fellow at the Hammersmith Hospital before completed SpR training at The Royal Marsden Hospital. He has been a consultant Medical Oncologist at the Kent Oncology Centre since 2006 and focuses on thoracic malignancies and clinical trials. He is a member of the BTOG steering committee and has previously served on the NCRI lung group.

If you would like to virtually connect with an MSD representative, please email us to set up an appointment:

Request an appointment

For more information about KEYTRUDA in NSCLC:

Visit Product page

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01553 | Date of Preparation: April 2021